Making complex and innovative products at scale, the next frontier, say pharma chiefs

(left to proper) Moderator – Sathya Prathipati , Senior Associate, McKinsey & Co talking with  Madan Mohan Reddy – Wholetime Director with Aurobindo Pharma, Nilesh Gupta – Lupin Managing Director, Dilip Shanghvi – Solar Prescribed drugs Govt Chairman and Sharvil Patel, Managing Director, Zydus Lifesciences and President, Indian Pharmaceutical Alliance (IPA).

The Indian pharmaceutical business has achieved scale in making generic medicines, however the next frontier is in making complex and innovative products and undertake new capabilities together with AI, as they face geo-political headwinds, amongst different challenges, stated the top-management of main pharmaceutical corporations.

Making products which might be inexpensive will probably be at the core, provided that Indian drugmakers are capable of make inexpensive variations of present and newer products, stated Sharvil Patel, Managing Director, Zydus Lifesciences and President, Indian Pharmaceutical Alliance (IPA). The journey now could be to construct “innovation at scale”, he stated, and that could possibly be accomplished by co-development, licensing or collaborations, he stated, talking at a panel dialogue on the closing day of the High quality Summit organised by the IPA – a platform largely for home drugmakers.

Solar Prescribed drugs Govt Chairman Dilip Shanghvi known as for a recalibration of the pharma business’s generic pondering, when it comes to funding choices, for instance.  Stating that he didn’t see “innovation at scale” but in the business, Shanghvi put it right down to the lack of “familiarity” with the decision-making course of, for instance, on this panorama.  The mindset wants to vary from bringing out products “cheaper and higher” to “sooner and higher”, he stated. And as extra corporations begin to achieve this journey, it might construct the confidence of others in the business, he added.  Lupin Managing Director Nilesh Gupta additionally identified the want for extra success tales. Citing Glenmark’s success with out-licensing a potential drug molecule, he stated, “we’d like 10 extra of this.”

Madan Mohan Reddy, Entire Time Director with Aurobindo Pharma, stated the current analysis spends of corporations was not sufficient to innovate. The next decade will contain a lot change, he stated, and the approach forward could be by extra partnerships and collaborations, he stated, with a powerful accent on high quality.

Revealed on February 24, 2026